RESUMO
ABSTRACT Introduction: Using gene therapy to transfer specific genes to implant therapeutic proteins into damaged tissues is a more promising way to treat sports injuries. The combination of tissue engineering and gene therapy will potentially promote the regeneration and repair of various damaged tissues. Objective: This article explores the adaptive relationship between gene selection therapy and athletes in sports. Methods: We selected students of related majors in sports schools to conduct specific genetic testing and measure the muscle area, fatigue level, muscle damage, and other related indicators before and after exercise. Results: After a series of physical fitness assessments, an increase in the gene sequence, as well as changes in the biochemical indices, were confirmed Conclusions: The muscle gain of the test subject during training is better than other genotypes. Level of evidence II; Therapeutic studies - investigation of treatment results.
RESUMO Introdução: A terapia gênica para transferir genes específicos para codificar proteínas terapêuticas para tecidos danificados é uma forma bastante promissora de tratar lesões esportivas. A combinação de engenharia de tecidos e terapia gênica possivelmente promoverá regeneração e reparo de vários tecidos danificados. Objetivo: Este artigo explora a relação adaptativa entre a terapia de seleção gênica e atletas no esporte. Métodos: Selecionamos alunos universitários nas escolas de esportes para realizar testes genéticos específicos e medir a área muscular, nível de fadiga, lesões musculares e outros indicadores relacionados antes e depois do exercício. Resultados: Depois de uma série de avaliações da aptidão física, verificou-se aumento da sequência gênica, assim como índices bioquímicos também apresentaram alterações. Conclusões: O ganho muscular dos indivíduos testados durante o treinamento é melhor do que outros genótipos. Nível de Evidência II; Estudos terapêuticos - Investigação dos resultados do tratamento.
RESUMEN Introducción: La terapia génica para transferir genes específicos que codifiquen proteínas terapéuticas a los tejidos dañados es una forma muy prometedora de tratar las lesiones deportivas. La combinación de ingeniería tisular y terapia génica posiblemente favorecerá la regeneración y reparación de diversos tejidos dañados. Objetivo: Este artículo explora la relación adaptativa entre la terapia de selección génica y los atletas en el deporte. Métodos: Se seleccionaron estudiantes universitarios de escuelas deportivas para realizar pruebas genéticas específicas y medir el área muscular, el nivel de fatiga, las lesiones musculares y otros indicadores relacionados antes y después del ejercicio. Resultados: Tras una serie de evaluaciones de acondicionamiento físico, se comprobó un aumento de la secuencia génica, y los índices bioquímicos también presentaron cambios. Conclusiones: El aumento de la masa muscular de los individuos analizados durante el entrenamiento es mejor que el de otros genotipos. Nivel de Evidencia II; Estudios terapéuticos - Investigación de los resultados del tratamiento.
RESUMO
Breast cancer is one of the most serious diseases, posing threats to women's physical and mental health. Gene therapy has been gradually regarded as an important part of tumor therapeutics. In the present study, the breast cancerspecific gene 1small interference RNA (BCSG1siRNA) plasmid was designed, then encapsulated by chitosansilicon dioxide nanometer carriers. The results demonstrated a successful encapsulation of BCSG1siRNA in chitosansilicon dioxide nanoparticles (encapsulation efficiency exceeded 90%). BCSG1siRNA was released slowly (the release rate was almost 30% after 24 h). The cytotoxic effect on MCF7 cells was enhanced by increasing the concentration of nanoparticle (the proliferation rate was reduced to 13.4±5.3% and apoptosis rate was increased to 71.5±6.8%). Therefore, the materials presented in the current study acted as successful gene carriers and exhibited significant antitumor effects in breast cancer cells.
Assuntos
Nanopartículas , Proteínas de Neoplasias/genética , RNA Interferente Pequeno/genética , Dióxido de Silício , gama-Sinucleína/genética , Apoptose/genética , Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Linhagem Celular Tumoral , Proliferação de Células , Células Cultivadas , Feminino , Regulação Neoplásica da Expressão Gênica , Inativação Gênica , Humanos , Imuno-Histoquímica , Interferência de RNA , RNA Interferente Pequeno/administração & dosagem , Dióxido de Silício/químicaRESUMO
PURPOSE: To compare the dose distribution characteristics of tumor target area, normal tissues and organs at risk in patients with malignant gliomas treated with intensity- modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT). METHODS: Plans of IMRT and 3DCRT were designed for each of the 96 included patients with malignant gliomas. Tumor dose was 60 Gy, and the dose distribution differences between the target area and normal tissues were compared using dose-volume histogram (DVH). RESULTS: Gross tumor volume (GTV) doses for 95% of the volume in the plans of IMRT and 3DCRT were as follows: 59.82±0.43, 57.68±0.62 Gy (p<0.05); clinical target volume (CTV): 58.16±0.48, 54.47±0.28 Gy (p<0.05); and planning treatment volume (PTV): 57.38±0.74, 54.21±0.48 Gy (p<0.05). The conformal index (CI) values of IMRT and 3DCRT plans were 0.92±0.15 and 0.73±0.12, respectively (p<0.05), whereas the homogeneity index (HI) values variability of IMRT and 3DCRT were 0.78±0.12 and 1.13±0.09 respectively (p<0.05). For normal brain tissues pituitary and optic chiasm, the maximum dose (Dmax) and the mean dose (Dmean) of lens exposure differed significantly between thw two plans (p<0.05). CONCLUSION: The target dose distribution of IMRT was superior to that of 3DCRT in terms of rationality, uniformity and conformal nature. IMRT may be better in protecting normal tissue and increasing the tumor radiation dose compared with 3DCRT.